Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).   LUPKYNIS was approved by the U.S. FDA in January 2021 for use in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN, and is the first FDA-approved oral therapy for LN.   Catalent will manufacture LUPKYNIS as a softgel dosage form at its pharmaceutical softgel center...